Sangeeta N. Bhatia

CIK: 0001643921

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (62.5%)

Position reduction

Option Exercises (M)1 (12.5%)

Derivative conversions

Awards (A)2 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VRTX

VERTEX PHARMACEUTICALS INC / MA

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

VRTX
VERTEX PHARMACEUTICALS INC / MA
May 4, 2026
Sale(S)
Direct
318 shares at avg. $423.73$135K
VRTX
VERTEX PHARMACEUTICALS INC / MA
May 1, 2026
Award(A)
Direct
943 shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 13, 2026
Sale(S)
Direct
266 shares at avg. $500.00$133K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Aug 27, 2025
Sale(S)
Direct
266 shares at avg. $386.69$103K
VRTX
VERTEX PHARMACEUTICALS INC / MA
May 2, 2025
Sale(S)
Direct
400 shares at avg. $505.86$202K
VRTX
VERTEX PHARMACEUTICALS INC / MA
May 1, 2025
Award(A)
Direct
796 shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Aug 30, 2024
Exercise(M)
Direct
646 shares at avg. $152.74$99K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Aug 30, 2024
Sale(S)
Direct
646 shares at avg. $500.00$323K

		Type	Shares	Price		Ownership
May 4, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	318	$423.73	$134,746	Direct
May 1, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A)	943	-	$0	Direct
Feb 13, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	266	$500.00	$133,000	Direct
Aug 27, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	266	$386.69	$102,860	Direct
May 2, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	400	$505.86	$202,344	Direct
May 1, 2025	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A)	796	-	-	Direct
Aug 30, 2024	VRTX VERTEX PHARMACEUTICALS INC / MA	Exercise(M)	646	$152.74	$98,670	Direct
Aug 30, 2024	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	646	$500.00	$323,000	Direct

1-8 of 8 transactions

About Bhatia Sangeeta N.

Bhatia Sangeeta N. (SEC CIK 0001643921) files insider reports with the SEC as Director of VERTEX PHARMACEUTICALS INC / MA (VRTX).

Signal8 holds 5 ownership filings by Bhatia Sangeeta N., all Form 4s, filed between Sep 4, 2024 and May 5, 2026. Those filings report 8 transactions, from Aug 30, 2024 to May 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Bhatia Sangeeta N.'s filings is in BOSTON, MA.

Recent filings by Bhatia Sangeeta N.

May 4, 2026: Open-market sale of VRTX shares (Form 4, code S).
May 1, 2026: Grant or award of VRTX shares (Form 4, code A).
Feb 13, 2026: Open-market sale of VRTX shares (Form 4, code S).
Aug 27, 2025: Open-market sale of VRTX shares (Form 4, code S).
May 2, 2025: Open-market sale of VRTX shares (Form 4, code S).

Other insiders filing for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Brennan Daniel J., Director
SACHS BRUCE I, Director
Garber Alan M, Director
van Grunsven Jasper, EVP, CP and NPPO
Ambrose Kristen, SVP & Chief Accounting Officer
Tatsis Ourania, EVP, Chief Reg. & Quality Off.

How to read Form 4 transaction codes